Reata Pharmaceuticals competitors and similar companiesClear all

Reata Pharmaceuticals's competitors and similar companies include Apellis Pharmaceuticals, Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Kadmon.

	Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.	Apellis Pharmaceuticals Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of therapeutic compounds.	Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.	Kadmon Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C.
Founding Date	Founding Date 2002	Founding Date 2009	Founding Date 2002	Founding Date 1989	Founding Date 2010
Type	Type Public	Type Public	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development medtech pharma	Tags Healthcare biotech healthtech pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development holding company pharma
Locations	Locations Plano, US HQ Irving, US Plano, US	Locations Waltham, US HQ München, DE Zug, CH San Francisco, US Watertown, US	Locations Cambridge, US HQ Paris, FR Milan, IT Tokyo, JP Amsterdam, NL Stockholm, SE Zug, CH see more	Locations Carlsbad, US HQ	Locations New York, US HQ Cambridge, US South Brunswick Township, US Warrendale, US
Employees	Employees 22079% increase	Employees 47627% increase	Employees 1,32324% increase	Employees 7577% decrease	Employees 1151% decrease
Valuation ($)	Valuation ($) 1.4 b	Valuation ($) 4.9 b	Valuation ($) 27.7 b	Valuation ($) 5.6 b	Valuation ($) N/A
Twitter followers	Twitter followers 1.3 k	Twitter followers 1.3 k	Twitter followers 16 k	Twitter followers 4.3 k	Twitter followers N/A
Number of tweets (last 30 days)	Number of tweets (last 30 days) 6	Number of tweets (last 30 days) 7	Number of tweets (last 30 days) 27	Number of tweets (last 30 days) 8	Number of tweets (last 30 days) N/A
Average likes per tweet (last 30 days)	Average likes per tweet (last 30 days) 2.3	Average likes per tweet (last 30 days) 3.9	Average likes per tweet (last 30 days) 9.1	Average likes per tweet (last 30 days) 6.4	Average likes per tweet (last 30 days) N/A
Percentage of tweets with engagement (last 30 days)	Percentage of tweets with engagement (last 30 days) 100%	Percentage of tweets with engagement (last 30 days) 85.71%	Percentage of tweets with engagement (last 30 days) 100%	Percentage of tweets with engagement (last 30 days) 100%	Percentage of tweets with engagement (last 30 days) N/A
Alexa Website Rank	Alexa Website Rank 267230	Alexa Website Rank 184577	Alexa Website Rank 376993	Alexa Website Rank 333062	Alexa Website Rank N/A
Employee Rating	Employee Rating 3.6	Employee Rating 3.8	Employee Rating 4.2	Employee Rating 3.6	Employee Rating 2.8
Financial
Revenue (est.)	Revenue (est.) $11.5m (FY, 2021)	Revenue (est.) $66.6m (FY, 2021)	Revenue (est.) $844.3m (FY, 2021)	Revenue (est.) $810.5m (FY, 2021)	Revenue (est.) $8.3m (FY, 2020)
Cost of goods	Cost of goods N/A	Cost of goods $200k (FY, 2021)	Cost of goods $115m (FY, 2021)	Cost of goods $10.8m (FY, 2021)	Cost of goods N/A
Net income	Net income ($297.4m) (FY, 2021)	Net income ($746.4m) (FY, 2021)	Net income ($852.8m) (FY, 2021)	Net income ($28.6m) (FY, 2021)	Net income ($108.9m) (FY, 2020)
Operating ⚠
Phase I Trials Products	Phase I Trials Products 2 (FY, 2016)	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 6 (FY, 2020)	Phase I Trials Products N/A
Phase II Trials Products	Phase II Trials Products 4 (FY, 2016)	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products 24 (FY, 2020)	Phase II Trials Products N/A
Phase III Trials Products	Phase III Trials Products 1 (FY, 2016)	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 6 (FY, 2020)	Phase III Trials Products N/A
Funding
Total funding raised	Total funding raised $ 468.9m	Total funding raised $ 88m	Total funding raised $ 1.5b	Total funding raised N/A	Total funding raised $ 21.3m